Cytovation builds on over 15 years of cutting-edge research from two leading Norwegian institutions; University of Bergen and Haukeland University Hospital.

Led by a highly experienced management team and world-renowned experts in tumor biology, an extensive research program has focused on engineering highly stable synthetic peptides with unique, antitumoral properties.

CY-101, the company’s lead candidate is being developed as a novel, first-in-class immunotherapy, that drives a tumor-specific immune response with a dual mode of action.